Methods of treatment using antagonists of cytokine synthesis inhibitory factor
AssigneeSchering Corporation
InventorsTimothy R. Mosmann, Kevin W. Moore, Martha W. Bond, Paulo J. M. Vieira
Life of this patent
Estimating the term…
Abstract
Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs, now known as Interleukin-10 (IL-10)), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-γ.
Claims9
A method of suppressing a humoral immune response in a human patient comprising administering to the patient an antibody against human cytokine synthesis inhibitory factor in an amount effective to block the biological activity (if human cytokine synthesis inhibitory factor.
A method of suppressing a humoral immune response in a human patient comprising administering to the patient a binding site from an antibody to said human cytokine synthesis inhibitory factor in an amount effective to block this biological activity of human cytokine synthesis inhibitory factor.
A method of suppressing a humoral immune response in a human patient comprising administering to the patient an antibody fragment against human cytokine synthesis inhibitory factor in an amount effective to block the biological activity of human cytokine synthesis inhibitory factor.
A method of suppressing a humoral immune response in a human patient comprising administering to the patient a binding composition specific for human cytokine synthesis inhibitory factor in an amount effective to block the biological activity of human cytokine synthesis inhibitory factor.
Dependencies are inferred from the claim text.